BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

746 related articles for article (PubMed ID: 2354413)

  • 1. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas.
    Lavey RS; Eby NL; Prosnitz LR
    Cancer; 1990 Jul; 66(1):80-8. PubMed ID: 2354413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second neoplasms in patients with Hodgkin's disease following combined modality therapy--the Yale experience.
    Koletsky AJ; Bertino JR; Farber LR; Prosnitz LR; Kapp DS; Fischer D; Portlock CS
    J Clin Oncol; 1986 Mar; 4(3):311-7. PubMed ID: 3950674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
    Rodriguez MA; Fuller LM; Zimmerman SO; Allen PK; Brown BW; Munsell MF; Hagemeister FB; McLaughlin P; Velasquez WS; Swan F
    Ann Oncol; 1993 Feb; 4(2):125-31. PubMed ID: 8448080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study.
    Cimino G; Papa G; Tura S; Mazza P; Rossi Ferrini PL; Bosi A; Amadori S; Lo Coco F; D'Arcangelo E; Giannarelli D
    J Clin Oncol; 1991 Mar; 9(3):432-7. PubMed ID: 1999712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
    Mauch PM; Kalish LA; Marcus KC; Coleman CN; Shulman LN; Krill E; Come S; Silver B; Canellos GP; Tarbell NJ
    Blood; 1996 May; 87(9):3625-32. PubMed ID: 8611686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second solid malignancies after combined modality therapy for Hodgkin's disease.
    Doria R; Holford T; Farber LR; Prosnitz LR; Cooper DL
    J Clin Oncol; 1995 Aug; 13(8):2016-22. PubMed ID: 7636543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Second malignant disease in patients under treatment for malignant lymphoma].
    Várady E; Molnár Z; Schneider T; Fleischmann T
    Orv Hetil; 1995 Oct; 136(43):2323-8. PubMed ID: 7478476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
    Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
    Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of leukemia following treatment for non-Hodgkin's lymphoma.
    Travis LB; Curtis RE; Stovall M; Holowaty EJ; van Leeuwen FE; Glimelius B; Lynch CF; Hagenbeek A; Li CY; Banks PM
    J Natl Cancer Inst; 1994 Oct; 86(19):1450-7. PubMed ID: 8089863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second neoplasms in Hodgkin's disease: current controversies.
    Zarrabi MH; Rosner F
    Hematol Oncol Clin North Am; 1989 Jun; 3(2):303-18. PubMed ID: 2663829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of second cancers after treatment for Hodgkin's disease.
    Tucker MA; Coleman CN; Cox RS; Varghese A; Rosenberg SA
    N Engl J Med; 1988 Jan; 318(2):76-81. PubMed ID: 3336397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.
    Sont JK; van Stiphout WA; Noordijk EM; Molenaar J; Zwetsloot-Schonk JH; Willemze R; Vandenbroucke JP
    Ann Hematol; 1992 Nov; 65(5):213-8. PubMed ID: 1457578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of second cancers in patients treated for Hodgkin's disease.
    Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
    J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
    Stone RM; Neuberg D; Soiffer R; Takvorian T; Whelan M; Rabinowe SN; Aster JC; Leavitt P; Mauch P; Freedman AS
    J Clin Oncol; 1994 Dec; 12(12):2535-42. PubMed ID: 7989927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
    Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
    Valagussa P; Santoro A; Fossati-Bellani F; Banfi A; Bonadonna G
    J Clin Oncol; 1986 Jun; 4(6):830-7. PubMed ID: 3711960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease.
    Beaty O; Hudson MM; Greenwald C; Luo X; Fang L; Wilimas JA; Thompson EI; Kun LE; Pratt CB
    J Clin Oncol; 1995 Mar; 13(3):603-9. PubMed ID: 7884422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.